Focused On-demand Library for Glutamate receptor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P42261

UPID:

GRIA1_HUMAN

Alternative names:

AMPA-selective glutamate receptor 1; GluR-A; GluR-K1; Glutamate receptor ionotropic, AMPA 1

Alternative UPACC:

P42261; B7Z2S0; B7Z2W8; B7Z3F6; B7Z9G9; D3DQI4; E7ESV8; Q2NKM6

Background:

Glutamate receptor 1, known by alternative names such as AMPA-selective glutamate receptor 1, GluR-A, GluR-K1, and Glutamate receptor ionotropic, AMPA 1, plays a pivotal role in the central nervous system. It functions as an ionotropic glutamate receptor, where L-glutamate, an excitatory neurotransmitter, induces a conformation change leading to cation channel opening. This process converts chemical signals to electrical impulses, essential for synaptic transmission.

Therapeutic significance:

Glutamate receptor 1 is implicated in Intellectual developmental disorder, autosomal dominant 67, and Intellectual developmental disorder, autosomal recessive 76, both characterized by developmental delays and impaired intellectual development. Understanding the role of Glutamate receptor 1 could open doors to potential therapeutic strategies for these disorders.